Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

Abstract The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline–trospium) on cognition in schizophrenia from the 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 trial...

Full description

Bibliographic Details
Main Authors: Colin Sauder, Luke A. Allen, Elizabeth Baker, Andrew C. Miller, Steven M. Paul, Stephen K. Brannan
Format: Article
Language:English
Published: Nature Publishing Group 2022-11-01
Series:Translational Psychiatry
Online Access:https://doi.org/10.1038/s41398-022-02254-9

Internet

https://doi.org/10.1038/s41398-022-02254-9

Similar Items